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HMGB1 has recently been implicated in a number of human cancers including 
colon, gastric, lung, and liver. The role of HMGB1 (a chromatin binding protein) in 
processes relevant to cancer cell survival include autophagy (Tang et al, 2010; Sun 
& Tang, 2014), genome stability (Liu et al), angiogenesis (Yang et al, 2014), 
invasion and metastasis (Yan et al, 2012). HMGB1 has a complex range of 
functions depending in part on its subcellular and extracellular localisation, redox 
state, and interaction with other cell surface receptors. Extracellular secretion of 
HMGB1 can maintain tumour cell autophagy (by binding to beclin-1)(Kang et al, 
2010), as well as recruit and activate immune cells. HMGB1 expression can also 
regulate the mitochondrial bioenergetics of cancer cells by enhancing complex I 
activity, ATP production and subsequent proliferation and migration (Kang et al, 
2014). The redox status of HMGB1 is important in modulating its function 
(Rubartelli & Lotze, 2007). HMGB1 contains three cysteines at positions C23, C45 
and C106 that can be modified. The all reduced form of HMGB1 is a 
chemoattractant that mediates leukocyte recruitment. The disulphide form has 
cytokine (but not chemokine) activity and can bind TLR4. The fully oxidised form of 
HMGB1 induced by reactive oxygen species (ROS) has neither cytokine nor 
chemoattractant activity. 
 
However the prognostic value of HMGB1 in ovarian cancer remains unclear. There 
is an important need to understand the context-dependent role of HMGB1 as either 
an anti- or pro-tumourogenic protein in ovarian cancer. To achieve this, the 
expression and prognostic value of HMGB1 was examined using two independent 
tissue microarrays. A large cohort of test (n=360) and validation (n=194) tumour 
samples were analysed to determine the effect on survival and the utility of HMGB1 
as an independent prognostic marker. 
 
 
 
 
Patient samples 
This is a retrospective study with patients comprehensively staged according to the 
International Federation of Obstetricians and Gynecologists (FIGO) staging system 
for ovarian cancer. Clinical details of test (n=360) (Popple et al, 2012) and 
validation (n=194) (Abdel-Fatah et al, 2013) cohorts have been previously 
described. This work was approved by the Derby Royal Hospital Ethics Committee 
and Nottingham Research Ethics Committee. 
 
Tissue Microarray and immunohistochemistry 
Tissue microarrays were constructed as described previously (Woolston et al, 
2010; Popple et al, 2012; Abdel-Fatah et al, 2013). Immunohistochemical staining 
was performed using a routine streptavidin–biotin peroxidase method. Sections 
were incubated with a Rabbit anti HMGB1 mAb (clone D3E5) (New England 
Biolabs, Hitchin, UK). Pearson's χ2-tests were used to determine the significance 
of associations between categorical variables. Survival rates were calculated using 
the Kaplan–Meier method; differences between survival curves were tested using 
the log-rank test. The Cox proportional-hazards model was used for multivariate 
analysis in order to calculate the Hazard ratios and independent significance of 
individual factors. In all cases two-sided P-values of <0.05 were considered as 
statistically significant.  
 
Statistical analysis 
Statistical analysis was performed using SPSS20 statistical software (SPSS Inc., 
Chicago, IL, USA). Pearson's χ2-tests were used to determine the significance of 
associations between categorical variables. Survival rates were calculated using 
the Kaplan–Meier method; differences between survival curves were tested using 
the log-rank test. The Cox proportional-hazards model was used for multivariate 
analysis in order to calculate the Hazard ratios and independent significance of 
individual factors. In all cases two-sided P-values of <0.05 were considered as 
statistically significant. 
 
Introduction 
Methods 
Our results indicate that high expression of HMGB1 is deleterious in ovarian 
cancer. The role of DAMPs in cancer is complex and is likely to be tumour specific 
as well as contingent on the redox state of HMGB1 , its subcellular localisation and 
the expression of corresponding ligands. Gene expression data from previous work 
suggest HMGB1 may correlate with poor survival in ovarian cancer (Chen et al, 
2012). However, to our knowledge this is the first large scale analysis of HMGB1 
protein expression in ovarian cancer with validation in an independent second 
cohort.  
Our work using large test and validation cohorts from ovarian cancer patients 
demonstrates that HMGB1 represents an independent prognostic marker of poor 
prognosis and that better understanding of HMGB1 in ovarian carcinoma 
pathogenesis may allow the rationale design of agents that target the HMGB1 
pathway in ovarian cancer. 
Discussion 
References 
In the test cohort 360 ovarian tumours were stained for HMGB1 (Table 1). 10% 
could not be evaluated due to the absence of enough tissue core or no evaluable 
tumour cells (i.e. all stroma) in the core. Of the 316 evaluable  ovarian tumours 
stained with a HMGB1 specific antibody, only 23/31660 (7%) tumours failed to 
stain. A further 42/316 (13%) stained weakly, 251/316 (79%)  stained strongly 
(Figure 1). Kaplan-Meier analysis showed there was a correlation of HMGB1 
expression and overall survival with low expression of HMGB1 being protective 
(p=0.002 ). This was replicated in the second cohort (overall survival p=0.077, 
progression free survival p=0.023) (Figure 2). The data indicates that there was a 
correlation of HMGB1 expression and survival where low expression of HMGB1 
gave an almost 2 fold increase in survival time from 55.7 months to 104.2 months 
(Table 2) After multivariate analysis HMGB1 remained an independent prognostic 
factor (p=0.006) (Table 3). In a multivariate model FIGO stage (p<0.0001), 
response to chemotherapy (p<0.0001), and HMGB1 expression (p=0.006) were 
independent predictors of patient survival.  
Figure 1. Representative photomicrographs of ovarian TMA cores immunohistochemically 
strained for HMGB1. The level of expression ranged from (A) Negative, (B) Weak, (C) 
Intermediate and (D) Strong expression.  
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Variable Categories 
Frequency of 
total cohort 
(%), n=360 
Frequency of 
the HMGB1-
stained cohort 
(%), n=316 
SEER age 
characteristics 
<30 years at diagnosis 2 (<1) 1 (<1) 
30–60 years at 
diagnosis 
143 (40) 127 (40) 
>60 years at diagnosis 212 (59) 190 (59) 
Unknown 3 (<1) 3 (1) 
    
Macroscopic 
residual disease 
Absent 143 (40) 126 (39) 
Present 201 (56) 180 (56) 
Unknown 16 (4) 15 (5) 
    
FIGO stage 
I 95 (26) 88 (27) 
II 38 (11) 34 (11) 
III 175 (49) 155 (48) 
IV 40 (11) 33 (10) 
Unknown 12 (3) 11 (3) 
    
Histological type 
Serous carcinoma 178 (49) 159 (50) 
Mucinous 
cystoadenocarcinoma 
35 (10) 31 (10) 
Endometrioid 42 (12) 39 (12) 
Clear cell 25 (7) 25 (8) 
Undifferentiated 54 (15) 47 (15) 
Others 26 (7) 20 (6) 
    
Serous tumour 
grade 
High 160 (44) 142 (44) 
Low 18 (5) 17 (5) 
    
Tumour grade of 
all other tumours 
Well differentiated (3) 100 (28) 91 (28) 
Moderately 
differentiated (2) 
39 (11) 35 (11) 
Poorly differentiated 
(1) 
20 (6) 19 (6) 
Unknown 23 (6) 17 (5) 
    
Adjuvant therapy 
No 101 (28) 92 (29) 
Yes 249 (69) 220 (69) 
Figure 2. Kaplan Meier curves showing overall ovarian cancer speciﬁc survival in (A) the test cohort (high 
expression with cut point value >4) and (B) overall ovarian cancer speciﬁc survival and (C) progression free 
survival in ovarian cancer patients in the validation cohort (high expression with cut point value >42) 
Table 1. Clinicopathological variables for the test patient cohort (n=360) and cores stained for 
HMGB1. 
 Exp(B) 
95% CI for Exp(B) 
P-value Lower Upper 
FIGO stage 
 Stage 1 1   <.001 
 Stage 2 
3.350 1.918 5.852 
 
 Stage 3 
7.886 4.896 12.704 
  
 Stage 4 
10.021 5.810 17.284 
 
  
 
      
Histological type 
 
 
    0.467 
Borderline 1 
   
Clear cell OVCA 1.130 0.479 2.667  
Mucinous OVCA 1.695 0.767 3.744  
Endometrioid OVCA 1.339 0.606 2.962  
Serous OVCA 1.594 0.796 3.195  
Undifferentiated OVCA 1.598 0.761 3.354  
Other OVCA 3.180 0.960 10.533  
          
Adjuvant therapy 
 No 1     <.001 
 Yes 0.361 0.240 0.541  
          
HMGB1 
 Low 1     0.006 
 High 1.921 1.205 3.064 
 
 
Abbreviations: CI=confidence interval; FIGO=International Federation of Gynecology and Obstetrics. 
  The analysis is based on Cox multivariate regression model. 
  P-values <0.05 are accepted to be significant 
 
Results 
Expression Mean survival time (months) in relation to HMGB-1 
expression 
Estimate 
(months) 
95% 
confidence 
interval 
 
Lower 
bound 
Upper 
bound 
P-value 
Low 104.2 73.2 135.1 0.002 
High 55.7 45.4 65.9 
Overall 63.7 53.2 74.1 
 
Table 2. Mean survival time in relation to HMGB1 expression. 
Table 3. Multivariate analysis for overall cancer speciﬁc survival in 316 consecutive 
patients with epithelial ovarian cancer. 
 
